CD177P1: A Promising Drug Target and Biomarker (G653579)
CD177P1: A Promising Drug Target and Biomarker
CD177P1, also known as CD177, is a protein that is expressed in various tissues of the human body, including the nervous system, endothelial cells, and epithelial cells. It plays a crucial role in cell signaling, particularly in the regulation of cell adhesion and migration. CD177 has also been implicated in several diseases, including cancer, neurodegenerative disorders, and autoimmune diseases. As a result, targeting CD177P1 has become an attractive research focus in recent years.
CD177P1: Structure and Function
CD177P1 is a 21-kDa transmembrane protein that consists of an extracellular domain, a transmembrane domain, and an intracellular domain. The extracellular domain is involved in cell adhesion and interaction with other proteins, while the transmembrane domain is responsible for the protein's unique structure and function. The intracellular domain is involved in the regulation of cellular signaling pathways.
CD177P1 has been shown to play a critical role in cell adhesion and migration. It is a negative regulator of the cadherin/caret calcium ion gradient, which is responsible for maintaining the integrity of the intercellular adhesion. In addition, CD177P1 has been shown to regulate the migration of various cell types, including neural and epithelial cells.
CD177P1 has also been implicated in the regulation of angiogenesis, the process by which new blood vessels are formed. It has been shown to play a negative role in theAngiogenesis, by regulating the sprouting angiogenesis, which is the process by which new blood vessels grow from the tips of blood vessels.
CD177P1 as a drug target
CD177P1 has been identified as a potential drug target due to its involvement in multiple cellular processes that are associated with various diseases. One of the main reasons for its potential as a drug target is its critical role in the regulation of cell signaling pathways. As a negative regulator of the cadherin/caret calcium ion gradient, CD177P1 has been shown to play a crucial role in maintaining the integrity of intercellular adhesion. Therefore, targeting CD177P1 may be an effective way to treat diseases that are characterized by disrupted intercellular adhesion, such as cancer, neurodegenerative disorders, and autoimmune diseases.
Another reason why CD177P1 is an attractive drug target is its role in the regulation of angiogenesis. As mentioned earlier, CD177P1 has been shown to play a negative role in theAngiogenesis, by regulating the sprouting angiogenesis. Therefore, targeting CD177P1 may be an effective way to treat diseases that are characterized by disrupted angiogenesis, such as cancer, neurodegenerative disorders, and autoimmune diseases.
In addition, CD177P1 has also been shown to play a role in the regulation of cell signaling pathways that are associated with pain perception and neurodegenerative disorders. Therefore, targeting CD177P1 may also be an effective way to treat chronic pain and neurodegenerative disorders.
CD177P1 as a biomarker
CD177P1 has also been used as a biomarker in the diagnosis and monitoring of various diseases. For example, it has been used as a biomarker for cancer, by evaluating the expression of CD177P1 in cancer cells and comparing it to the expression of CD177P1 in normal tissue. Studies have shown that the expression of CD177P1 is significantly increased in cancer cells compared to normal tissue, making it a potential biomarker for cancer.
In addition, CD177P1 has also been used as a biomarker for neurodegenerative disorders, such as Alzheimer's disease and Parkinson's disease. Studies have shown that the expression of CD177P1 is significantly increased in the brains of individuals with neurodegenerative disorders compared to healthy individuals. This increase in CD177P1 expression may be a sign of neurodegeneration and could be used as a biomarker for the diagnosis and monitoring of these disorders.
Conclusion
In conclusion, CD177P1 is a protein that has been shown to play a crucial role in multiple cellular processes that are associated with various diseases. Its potential as a drug target and biomarker make it an attractive focus for research in the field ofCD177P1 targeting. Further studies are needed to fully understand its role in cell signaling pathways and its potential as a drug and biomarker.
Protein Name: CD177 Molecule Pseudogene 1
The "CD177P1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CD177P1 comprehensively, including but not limited to:
• general information;
• protein structure and compound binding;
• protein biological mechanisms;
• its importance;
• the target screening and validation;
• expression level;
• disease relevance;
• drug resistance;
• related combination drugs;
• pharmacochemistry experiments;
• related patent analysis;
• advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai
More Common Targets
CD180 | CD19 | CD1A | CD1B | CD1C | CD1D | CD1E | CD2 | CD200 | CD200R1 | CD200R1L | CD207 | CD209 | CD22 | CD226 | CD24 | CD244 | CD247 | CD248 | CD24P2 | CD27 | CD27-AS1 | CD274 | CD276 | CD28 | CD2AP | CD2BP2 | CD3 Complex (T Cell Receptor Complex) | CD300A | CD300C | CD300E | CD300LB | CD300LD | CD300LD-AS1 | CD300LF | CD300LG | CD302 | CD320 | CD33 | CD34 | CD36 | CD37 | CD38 | CD3D | CD3E | CD3G | CD4 | CD40 | CD40LG | CD44 | CD44-DT | CD46 | CD47 | CD48 | CD5 | CD52 | CD53 | CD55 | CD58 | CD59 | CD5L | CD6 | CD63 | CD68 | CD69 | CD7 | CD70 | CD72 | CD74 | CD79A | CD79B | CD8 | CD80 | CD81 | CD81-AS1 | CD82 | CD83 | CD84 | CD86 | CD8A | CD8B | CD8B2 | CD9 | CD93 | CD96 | CD99 | CD99L2 | CD99P1 | CDA | CDADC1 | CDAN1 | CDC123 | CDC14A | CDC14B | CDC14C | CDC16 | CDC20 | CDC20-DT | CDC20B | CDC20P1
